{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:20:55Z","timestamp":1773274855181,"version":"3.50.1"},"reference-count":38,"publisher":"Tohoku University Medical Press","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2018]]},"DOI":"10.1620\/tjem.244.33","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T22:18:00Z","timestamp":1516227480000},"page":"33-40","source":"Crossref","is-referenced-by-count":42,"title":["Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab"],"prefix":"10.1620","volume":"244","author":[{"given":"Kanako","family":"Sakurai","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, National Hospital Organization Sendai Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satsuki","family":"Niitsuma","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, National Hospital Organization Sendai Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, National Hospital Organization Sendai Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Applied Medical Science, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenei","family":"Arihara","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, National Hospital Organization Sendai Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","unstructured":"American Diabetes Association (1998) Diagnosis and classification of diabetes mellitus. <i>Diabetes Care<\/i>, 21, S5-S19."},{"key":"2","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2009) Diagnosis and classification of diabetes mellitus. <i>Diabetes Care<\/i>, 32, S62-S67.","DOI":"10.2337\/dc09-S062"},{"key":"3","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2014) Diagnosis and classification of diabetes mellitus. <i>Diabetes Care<\/i>, 37, S81-S90.","DOI":"10.2337\/dc14-S081"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Araujo, M., Ligeiro, D., Costa, L., Marques, F., Trindade, H., Correia, J.M. &amp; Fonseca, C. (2017) A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient. <i>Immunotherapy<\/i>, 9, 531-535.","DOI":"10.2217\/imt-2017-0020"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Awata, T., Kuzuya, T., Matsuda, A., Iwamoto, Y. &amp; Kanazawa, Y. (1992) Genetic analysis of HLA class II alleles and susceptibility to type 1 (insulin-dependent) diabetes mellitus in Japanese subjects. <i>Diabetologia<\/i>, 35, 419-424.","DOI":"10.1007\/BF02342437"},{"key":"6","unstructured":"Chae, Y.K., Chiec, L., Mohindra, N., Gentzler, R., Patel, J. &amp; Giles, F. (2017) A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. <i>Cancer Immunol. Immunother.<\/i>, 66, 25-32."},{"key":"7","unstructured":"Corsello, S.M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R. &amp; Torino, F. (2013) Endocrine side effects induced by immune checkpoint inhibitors. <i>J. Clin. Endocrinol. Metab.<\/i>, 98, 1361-1375."},{"key":"8","unstructured":"Dayan, C.M. &amp; Daniels, G.H. (1996) Chronic autoimmune thyroiditis. <i>N. Engl. J. Med.<\/i>, 335, 99-107."},{"key":"9","doi-asserted-by":"crossref","unstructured":"Gaudy, C., Clevy, C., Monestier, S., Dubois, N., Preau, Y., Mallet, S., Richard, M.A., Grob, J.J., Valero, R. &amp; Beliard, S. (2015) Anti-PD1 Pembrolizumab can induce exceptional fulminant type 1 diabetes. <i>Diabetes Care<\/i>, 38, e182-183.","DOI":"10.2337\/dc15-1331"},{"key":"10","unstructured":"Haanen, J.B., Thienen, H. &amp; Blank, C.U. (2015) Toxicity patterns with immunomodulating antibodies and their combinations. <i>Semin. Oncol.<\/i>, 42, 423-428."},{"key":"11","doi-asserted-by":"crossref","unstructured":"Hamasaki, A., Taniguchi, T., Yamane, S., Ida, M., Okamoto, M., Yamada, Y., Inagaki, N. &amp; Seino, Y. (2006) A case of fulminant type 1 diabetes associated with painless thyroiditis. <i>Diabetes Care<\/i>, 29, 946-947.","DOI":"10.2337\/diacare.29.04.06.dc05-2544"},{"key":"12","unstructured":"Hanafusa, T., Imagawa, A., Iwahashi, H., Uchigata, Y., Kanatsuka, A., Kawasaki, E., Kobayashi, T., Shimada, A., Shimizu, I., Maruyama, T. &amp; Makino, H. (2005) Report of Japan Diabetes Society Committee on Fulminant Type 1 Diabetes Mellitus Research: Epidemiological and clinical analysis and proposal of diagnosis criteria. <i>J. Japan Diab. Soc.<\/i>, 48 Supple 1, A1-A13."},{"key":"13","unstructured":"Hansen, E., Sahasrabudhe, D. &amp; Sievert, L. (2016) A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. <i>Cancer Immunol. Immunother.<\/i>, 65, 765-767."},{"key":"14","unstructured":"Hofmann, L., Forschner, A., Loquai, C., Goldinger, S.M., Zimmer, L., Ugurel, S., Schmidgen, M.I., Gutzmer, R., Utikal, J.S., G\u00f6ppner, D., Hassel, J.C., Meier, F., Tietze, J.K., Thomas, I., Weishaupt, C., et al. (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. <i>Eur. J. Cancer<\/i>, 60, 190-209."},{"key":"15","doi-asserted-by":"crossref","unstructured":"Hughes, J., Vudattu, N., Sznol, M., Gettinger, S., Kluger, H., Lupsa, B. &amp; Herold, K.C. (2015) Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. <i>Diabetes Care<\/i>, 38, e55-57.","DOI":"10.2337\/dc14-2349"},{"key":"16","unstructured":"Ikegami, H., Kawaguchi, Y., Yamato, E., Kuwata, S., Tokunaga, K., Noma, Y., Shima, K. &amp; Ogihara, T. (1992) Analysis by the polymerase chain reaction of histocompatibility leucocyte antigen-DR9-linked susceptibility to insulin-dependent diabetes mellitus. <i>J. Clin. Endocrinol. Metab.<\/i>, 75, 1381-1385."},{"key":"17","unstructured":"Imagawa, A., Hanafusa, T., Awata, T., Ikegami, H., Uchigata, Y., Osawa, H., Kawasaki, E., Kawabata, Y., Kobayashi, T., Shimada, A., Shimizu, I., Takahashi, K., Nagata, M., Makino, H. &amp; Maruyama, T. (2012) Report of the committee of the Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus. <i>J. Diabetes Investig.<\/i>, 3, 536-539."},{"key":"18","unstructured":"Imagawa, A., Hanafusa, T., Miyagawa, J. &amp; Matsuzawa, Y. (2000) A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM study group. <i>N. Engl. J. Med.<\/i>, 342, 301-307."},{"key":"19","doi-asserted-by":"crossref","unstructured":"Ishikawa, K., Shono-Saito, T., Yamate, T., Kai, Y., Sakai, T., Shimizu, F., Yamada, Y., Mori, H., Noso, S., Ikegami, H., Kojima, H., Tanaka, H., Fujiwara, S. &amp; Hatano, Y. (2017) A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms. <i>Eur. J. Dermatol.<\/i>, 27, 184-185.","DOI":"10.1684\/ejd.2016.2923"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Kawabata, Y., Ikegami, H., Awata, T., Imagawa, A., Maruyama, T., Kawasaki, E., Tanaka, S., Shimada, A., Osawa, H., Kobayashi, T., Hanafusa, T., Tokunaga, K. &amp; Makino, H.; Committee on Type 1 Diabetes, Japan Diabetes Society (2009) Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. <i>Diabetologia<\/i>, 52, 2513-2521.","DOI":"10.1007\/s00125-009-1539-9"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Kawabata, Y., Ikegami, H., Kawaguchi, Y., Fujisawa, T., Shintani, M., Ono, M., Nishino, M., Uchigata, Y., Lee, I. &amp; Ogihara, T. (2002) Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and -DQ haplotypes to susceptibility to type 1 diabetes. <i>Diabetes<\/i>, 51, 545-551.","DOI":"10.2337\/diabetes.51.2.545"},{"key":"22","unstructured":"Kong, S.H., Lee, S.Y., Yang, Y.S., Kim, T.M. &amp; Kwak, S.H. (2016) Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes. <i>Acta Diabetol.<\/i>, 53, 853-856."},{"key":"23","unstructured":"Li, L., Masood, A., Bari, S., Yavuz, S. &amp; Grosbach, A.B. (2017) Autoimmune diabetes and thyroiditis complicating treatment with nivolumab. <i>Case Rep. Oncol.<\/i>, 10, 230-234."},{"key":"24","unstructured":"Lowe, J.R., Perry, D.J., Salama, A.K., Mathews, C.E., Moss, L.G. &amp; Hanks, B.A. (2016) Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. <i>J. Immunother. Cancer<\/i>, 4, 89."},{"key":"25","unstructured":"Martin-Liberal, J., Furness, A.J., Joshi, K., Peggs, K.S., Quezada, S.A. &amp; Larkin, J. (2015) Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. <i>Cancer Immunol. Immunother.<\/i>, 64, 765-767."},{"key":"26","doi-asserted-by":"crossref","unstructured":"Mellati, M., Eaton, K.D., Brooks-Worrell, B.M., Hagopian, W.A., Martins, R., Palmer, J.P. &amp; Hirsch, I.B. (2015) Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing type 1 diabetes. <i>Diabetes Care<\/i>, 38, e137-138.","DOI":"10.2337\/dc15-0889"},{"key":"27","unstructured":"Miyoshi, Y., Ogawa, O. &amp; Oyama, Y. (2016) Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes. <i>Tohoku J. Exp. Med.<\/i>, 239, 155-158."},{"key":"28","unstructured":"Munakata, W., Ohashi, K., Yamauchi, N. &amp; Tobinai, K. (2017) Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. <i>Int. J. Hematol.<\/i>, 105, 383-386."},{"key":"29","unstructured":"Okamoto, M., Okamoto, M., Gotoh, K., Masaki, T., Ozeki, Y., Ando, H., Anai, M., Sato, A., Yoshida, Y., Ueda, S., Kakuma, T. &amp; Shibata, H. (2016) Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. <i>J. Diabetes Investig.<\/i>, 7, 915-918."},{"key":"30","doi-asserted-by":"crossref","unstructured":"Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F.S., Schachter, J., Pavlick, A.C., Lewis, K.D., Cranmer, L.D., Blank, C.U., O\u2019Day, S.J., Ascierto, P.A., Salama, A.K., et al. (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncol.<\/i>, 16, 908-918.","DOI":"10.1016\/S1470-2045(15)00083-2"},{"key":"31","unstructured":"Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K.J., Hernberg, M.M., Lebbe, C., Charles, J., Mihalcioiu, C., et al. (2015) Nivolumab in previously untreated melanoma without BRAF mutation. <i>N. Engl. J. Med.<\/i>, 372, 320-330."},{"key":"32","unstructured":"Ryder, M., Callahan, M., Postow, M.A., Wolchok, J. &amp; Fagin, J.A. (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. <i>Endocr. Relat. Cancer<\/i>, 21, 371-381."},{"key":"33","doi-asserted-by":"crossref","unstructured":"Shimada, A., Morimoto, J., Kodama, K., Oikawa, Y., Irie, J., Nakagawa, Y., Narumi, S. &amp; Saruta, T. (2002a) T-cell-mediated autoimmunity may be involved in fulminant type 1 diabetes. <i>Diabetes Care<\/i>, 25, 635-636.","DOI":"10.2337\/diacare.25.3.635"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Shimada, A., Oikawa, Y., Shigihara, T., Senda, T. &amp; Kodama, K. (2002b) A case of fulminant type 1 diabetes with strong evidence of autoimmunity. <i>Diabetes Care<\/i>, 25, 1482-1483.","DOI":"10.2337\/diacare.25.8.1482"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Taniguchi, T., Okazaki, K., Okamoto, M., Seko, S., Nagashima, K., Yamada, Y., Iwakura, T. &amp; Seino, Y. (2005) Autoantibodies against the exocrine pancreas in fulminant type 1 diabetes. <i>Pancreas<\/i>, 30, 191-192.","DOI":"10.1097\/01.mpa.0000148508.95423.1d"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Taniguchi, T., Tanaka, J., Seko, S., Okazaki, K. &amp; Okamoto, M. (2001) Association of rapid-onset type 1 diabetes and clinical acute pancreatitis positive for autoantibodies to the exocrine pancreas. <i>Diabetes Care<\/i>, 24, 2156-2157.","DOI":"10.2337\/diacare.24.12.2156"},{"key":"37","unstructured":"Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, C.G., et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. <i>N. Engl. J. Med.<\/i>, 366, 2443-2454."},{"key":"38","doi-asserted-by":"crossref","unstructured":"Yasunaga, S., Kimura, A., Hamaguchi, K., Ronningen, K.S. &amp; Sasazuki, T. (1996) Different contribution of HLA-DR and -DQ genes in susceptibility and resistance to insulin-dependent diabetes mellitus (IDDM). <i>Tissue Antigens<\/i>, 47, 37-48.","DOI":"10.1111\/j.1399-0039.1996.tb02512.x"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/244\/1\/244_33\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T19:40:57Z","timestamp":1660333257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/244\/1\/244_33\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.244.33","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}